BioVersys AG has announced the publication of two Phase 1 clinical pharmacology studies of its lead asset BV100 in the International Journal of Antimicrobial Agents and the Journal of Antimicrobial Chemotherapy, providing pivotal data on lung penetration and drug interactions that could shape the drug's future in treating severe hospital-acquired infections. The publications matter because they address critical pharmacological questions for an intravenous antibiotic intended for critically ill patients with limited treatment options, and they form part of the clinical foundation for the ongoing Phase 3 registration trial, RIV-TARGET.
The first paper, published in the International Journal of Antimicrobial Agents, details a study in 36 healthy male participants who received intravenous rifabutin (BV100) 300 mg every 12 hours for four days. Results showed that concentrations of rifabutin in lung fluid and alveolar macrophages exceeded plasma concentrations at every time point, with median penetration ratios of approximately 35-fold and over 300-fold, respectively. Repeated dosing was well tolerated. The authors concluded that these pulmonary exposures provide a strong pharmacological rationale for further clinical evaluation of BV100 in severe pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). The full study is available under DOI: 10.1016/j.ijantimicag.2026.108014.
The second paper, in the Journal of Antimicrobial Chemotherapy, reports two Phase 1 drug-drug interaction studies. BV100 was found to be a mild CYP3A inducer, reducing midazolam exposure by approximately 47%, and a mild substrate for CYP3A inhibitors, with rifabutin exposure increasing 1.3- to 1.7-fold when co-administered with itraconazole. This profile is milder than that of rifampicin, a strong CYP3A inducer, and BV100 was safe and well tolerated in both studies. The implications are significant for critical care, where patients often receive multiple medications; a milder interaction profile reduces the risk of complicating treatment regimens. The study is accessible via DOI: 10.1093/jac/dkag317.
These data are particularly important because CRABC infections are among the highest unmet medical needs in infectious disease, with limited treatment options and mortality rates up to 50%. BV100 is currently being studied in the pivotal Phase 3 global registrational trial, RIV-TARGET, and the open-label Phase 2b differentiation trial, RIV-CARE, in collaboration with ADVANCE-ID. Enrollment in RIV-TARGET is ongoing, with topline data anticipated in early 2028. BV100 received Fast Track Designation from the US FDA in September 2026, building on its Qualified Infectious Disease Product designation granted in 2019, which makes it eligible for priority review and a five-year extension of market exclusivity upon approval.
Dr. Glenn Dale, Chief Development Officer of BioVersys and co-author of the publications, commented that the papers address the questions that matter most for an intravenous antibiotic in critically ill pneumonia patients, noting that BV100 has very good distribution in lung fluid and alveolar macrophages and a mild, manageable drug-interaction profile. Dr. Marc Gitzinger, CEO and founder, added that carbapenem-resistant Acinetobacter baumannii represents one of the highest medical needs in infectious disease, and these data strengthen the scientific basis for BV100 therapy in CRABC pneumonia. The publications thus reinforce the rationale for the Phase 3 program and bring the company a step closer to delivering a much-needed new treatment option for patients and physicians.
